{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03579875",
            "orgStudyIdInfo": {
                "id": "2016LS161"
            },
            "secondaryIdInfos": [
                {
                    "id": "MT2017-17",
                    "type": "OTHER",
                    "domain": "Masonic Cancer Center, University of Minnesota"
                }
            ],
            "organization": {
                "fullName": "Masonic Cancer Center, University of Minnesota",
                "class": "OTHER"
            },
            "briefTitle": "Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders",
            "officialTitle": "MT2017-17:T Cell Receptor Alpha/Beta T Cell Depleted Hematopoietic Cell Transplantation in Patients With Inherited Bone Marrow Failure (BMF) Disorders",
            "therapeuticArea": [
                "Rare Diseases",
                "Other",
                "Orthopedics"
            ],
            "study": "alpha-beta-tcd-hct-in-patients-with-inherited-bmf-disorders"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-11-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-01-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-05-25",
            "studyFirstSubmitQcDate": "2018-07-06",
            "studyFirstPostDateStruct": {
                "date": "2018-07-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Masonic Cancer Center, University of Minnesota",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a phase II trial of T cell receptor alpha/beta depletion (\u03b1/\u03b2 TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation."
        },
        "conditionsModule": {
            "conditions": [
                "Fanconi Anemia",
                "Severe Aplastic Anemia",
                "Myelodysplastic Syndromes",
                "T Cell Receptor Alpha/Beta Depletion",
                "Telomere Biology Disorder",
                "Bone Marrow Failure",
                "Dyskeratosis Congenita"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 48,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP in patients with Fanconi Anemia",
                    "type": "EXPERIMENTAL",
                    "description": "Given to:\n\n* Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type OR\n* Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia",
                    "interventionNames": [
                        "Drug: Total Body Irradiation (TBI) (Plan 1)",
                        "Drug: Cyclophosphamide (CY) (Plan 1)",
                        "Drug: Fludarabine (FLU)",
                        "Drug: Methylprednisolone (MP)",
                        "Device: Donor mobilized PBSC infusion",
                        "Drug: G-CSF",
                        "Drug: Rituximab"
                    ]
                },
                {
                    "label": "Treatment Plan 2: CY, FLU and MP in patients with Fanconi Anemia",
                    "type": "EXPERIMENTAL",
                    "description": "Given to:\n\n\u2022 HLA-identical sibling donor recipients with aplastic anemia",
                    "interventionNames": [
                        "Drug: Fludarabine (FLU)",
                        "Drug: Methylprednisolone (MP)",
                        "Device: Donor mobilized PBSC infusion",
                        "Drug: G-CSF",
                        "Drug: Cyclophosphamide (CY) (Plan 2)",
                        "Drug: Rituximab"
                    ]
                },
                {
                    "label": "Treatment Plan 3: BU, Cy, FLU, MP and Rituximab in patients with Fanconi Anemia",
                    "type": "EXPERIMENTAL",
                    "description": "Given to:\n\n* Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type who cannot tolerate TBI\n* Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia who cannot tolerate TBI\n* Per treating physician preference",
                    "interventionNames": [
                        "Drug: Cyclophosphamide (CY) (Plan 1)",
                        "Drug: Fludarabine (FLU)",
                        "Drug: Methylprednisolone (MP)",
                        "Drug: Rituximab",
                        "Drug: Busulfan"
                    ]
                },
                {
                    "label": "Treatment Plan 4: CY, FLU, and alemtuzumab",
                    "type": "EXPERIMENTAL",
                    "description": "given to TBD patients with:\n\n* Bone marrow failure AND\n* Any donor type including haploidentical (4/8) to 8/8-HLA matched related donor, or 7-8/8 HLA-matched unrelated donor Based on historical numbers, it is expected approximately 3 patients would be treated per year. Statistical outcomes will be descriptive.",
                    "interventionNames": [
                        "Drug: Cyclophosphamide (CY) (Plan 1)",
                        "Drug: Fludarabine (FLU)",
                        "Drug: Alemtuzumab"
                    ]
                },
                {
                    "label": "Treatment Plan 5: CY, FLU, melphalan (MEL), and alemtuzumab.",
                    "type": "EXPERIMENTAL",
                    "description": "given to TBD patients with:\n\n* Early MDS features (with or without cytogenetic abnormalities) AND\n* Any donor type including haploidentical (4/8) to 8/8-HLA matched related donor, or 7-8/8 HLA-matched unrelated donor Based on historical numbers, it is expected approximately 2 patients would be treated per year. Statistical outcomes will be descriptive.",
                    "interventionNames": [
                        "Drug: Cyclophosphamide (CY) (Plan 1)",
                        "Drug: Fludarabine (FLU)",
                        "Drug: Alemtuzumab",
                        "Drug: Melphalan"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Total Body Irradiation (TBI) (Plan 1)",
                    "description": "300 cGy with thymic shielding on day -6",
                    "armGroupLabels": [
                        "Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP in patients with Fanconi Anemia"
                    ],
                    "otherNames": [
                        "TBI"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide (CY) (Plan 1)",
                    "description": "10 mg/kg IV daily on days -5, -4, -3, and -2",
                    "armGroupLabels": [
                        "Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP in patients with Fanconi Anemia",
                        "Treatment Plan 3: BU, Cy, FLU, MP and Rituximab in patients with Fanconi Anemia",
                        "Treatment Plan 4: CY, FLU, and alemtuzumab",
                        "Treatment Plan 5: CY, FLU, melphalan (MEL), and alemtuzumab."
                    ],
                    "otherNames": [
                        "CY"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine (FLU)",
                    "description": "35 mg/m2 IV daily on days -5, -4, -3, and -2",
                    "armGroupLabels": [
                        "Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP in patients with Fanconi Anemia",
                        "Treatment Plan 2: CY, FLU and MP in patients with Fanconi Anemia",
                        "Treatment Plan 3: BU, Cy, FLU, MP and Rituximab in patients with Fanconi Anemia",
                        "Treatment Plan 4: CY, FLU, and alemtuzumab",
                        "Treatment Plan 5: CY, FLU, melphalan (MEL), and alemtuzumab."
                    ],
                    "otherNames": [
                        "FLU"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Methylprednisolone (MP)",
                    "description": "1 mg/kg IV q12h on days -5, -4, -3, -2, and -1",
                    "armGroupLabels": [
                        "Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP in patients with Fanconi Anemia",
                        "Treatment Plan 2: CY, FLU and MP in patients with Fanconi Anemia",
                        "Treatment Plan 3: BU, Cy, FLU, MP and Rituximab in patients with Fanconi Anemia"
                    ],
                    "otherNames": [
                        "MP"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "Donor mobilized PBSC infusion",
                    "description": "T cell receptor alpha/beta depletion (\u03b1/\u03b2 TCD) peripheral blood stem cell (PBSC) transplantation on day 0",
                    "armGroupLabels": [
                        "Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP in patients with Fanconi Anemia",
                        "Treatment Plan 2: CY, FLU and MP in patients with Fanconi Anemia"
                    ],
                    "otherNames": [
                        "PBSC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "G-CSF",
                    "description": "Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC \\>2.5 x 10\\^9/L for 3 consecutive days)",
                    "armGroupLabels": [
                        "Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP in patients with Fanconi Anemia",
                        "Treatment Plan 2: CY, FLU and MP in patients with Fanconi Anemia"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide (CY) (Plan 2)",
                    "description": "5 mg/kg IV daily on days -5, -4, -3, and -2",
                    "armGroupLabels": [
                        "Treatment Plan 2: CY, FLU and MP in patients with Fanconi Anemia"
                    ],
                    "otherNames": [
                        "CY"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Rituximab",
                    "description": "200 mg/m2 IV once on day -1",
                    "armGroupLabels": [
                        "Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP in patients with Fanconi Anemia",
                        "Treatment Plan 2: CY, FLU and MP in patients with Fanconi Anemia",
                        "Treatment Plan 3: BU, Cy, FLU, MP and Rituximab in patients with Fanconi Anemia"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Busulfan",
                    "description": "Busulfan 0.6 mg/kg if \\> 4 years old and/or \\>12 kg (0.8 mg/kg IV if \u2264 4 years old and/or \u2264 12 kg) is given IV over 2 hours every 12 hours for 2 days.",
                    "armGroupLabels": [
                        "Treatment Plan 3: BU, Cy, FLU, MP and Rituximab in patients with Fanconi Anemia"
                    ],
                    "otherNames": [
                        "BU"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Alemtuzumab",
                    "description": "Alemtuzumab 0.2 mg/kg is given IV over 2 hours daily for 5 days (total dose 1 mg/kg)",
                    "armGroupLabels": [
                        "Treatment Plan 4: CY, FLU, and alemtuzumab",
                        "Treatment Plan 5: CY, FLU, melphalan (MEL), and alemtuzumab."
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Melphalan",
                    "description": "If available, MEL dosing will be model-based using Bayesian methodology. If Bayesian methodology is unavailable, MEL dosing will be weight-based: MEL 70 mg/m2 for patients \u226510 kg (2.35 mg/kg for patients \\<10 kg\\^) IV for one dose over 30 minutes.",
                    "armGroupLabels": [
                        "Treatment Plan 5: CY, FLU, melphalan (MEL), and alemtuzumab."
                    ],
                    "otherNames": [
                        "MEL"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Grade II-IV acute graft versus host disease (GVHD)",
                    "description": "incidence of grade II-IV acute graft versus host disease (GVHD)",
                    "timeFrame": "Day 100"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Neutrophil engraftment",
                    "description": "Rate of neutrophil engraftment (defined as the first of three consecutive days after HCT that the patient's absolute neutrophil counts is \u2265 0.5x109 per liter)",
                    "timeFrame": "Day 42"
                },
                {
                    "measure": "Platelet engraftment",
                    "description": "Time to platelet engraftment (First of three consecutive days after HCT that the patient's platelet count \u2265 20x10\\^9 per liter)",
                    "timeFrame": "Day 42"
                },
                {
                    "measure": "Acute graft versus host disease (aGVHD)",
                    "description": "Incidence of grade III-IV acute graft versus host disease",
                    "timeFrame": "Day 100"
                },
                {
                    "measure": "Chronic graft versus host disease (cGVHD)",
                    "description": "Incidence of chronic graft versus host disease after transplant",
                    "timeFrame": "1 Year after transplant"
                },
                {
                    "measure": "Regimen related toxicity",
                    "description": "Incidence of regimen related toxicity based on CTCAE v5",
                    "timeFrame": "30 Days after transplant"
                },
                {
                    "measure": "Bacterial, viral and fungal infections",
                    "description": "Incidence of bacterial, viral and fungal infections",
                    "timeFrame": "1 Year after transplant"
                },
                {
                    "measure": "Opportunistic infections",
                    "description": "Incidence of opportunistic infections",
                    "timeFrame": "100 Days after transplant"
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "Incidence of overall survival",
                    "timeFrame": "1 Year after transplant"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Patient Selection:\n\nInclusion Criteria:\n\nFor FA patients:\n\n* Diagnosis of Fanconi anemia\n\n  * Age \\<65 years of age\n* Has one of the following risk factors:\n\n  * Severe aplastic anemia (SAA)\n  * Myelodysplastic syndrome (MDS)\n  * High risk genotype\n  * Immunodeficiency associated with history of recurrent infections\n* Karnofsky performance status \u2265 70% if \u2265 16 years of age or Lansky play score \u2265 50% for patients \\<16 years of age\n\n  * Adequate pulmonary, cardiac and liver function\n  * Voluntary written consent (minor assent if appropriate) prior to the performance of any study related procedures not part of standard medical care\n\nFor TBD patients:\n\n\u2022 Diagnosis of TBD\n\n* Age \\<70 years of age\n* Has one of the following risk factors:\n* Severe aplastic anemia (SAA)\n* Myelodysplastic syndrome (MDS)\n* Karnofsky performance status \u2265 70% if \u2265 16 years of age or Lansky play score\n\n  \u2265 50% for patients \\<16 years of age\n* Adequate pulmonary, cardiac and liver function\n* Voluntary written consent (minor assent if appropriate) prior to the performance of any study related procedures not part of standard medical care\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding as the treatment used in this study are Pregnancy Category D. Females of childbearing potential must have a negative pregnancy test (serum or urine) within 14 days of study registration\n* Active, uncontrolled infection within 1 week prior to starting study therapy\n* Malignant solid tumor cancer within previous 2 years\n\nDonor Selection (Inclusion Criteria): meets one of the following match criteria:\n\n* an HLA-A, B, DRB1 matched sibling donor (matched sibling)\n* an HLA-A, B, DRB1 matched related donor (other than sibling)\n* a related donor mismatched at 1 HLA-A, B, C and DRB1 antigen\n* 7-8/8 HLA-A,B,C,DRB1 allele matched unrelated donor per current institutional guidelines Patients and donors are typed for HLA-A and B using serological or molecular techniques and for DRB1 using high resolution molecular typing. If a donor has been selected on the basis of HLA-A, B, C and DRB1 typing as above, preference will be made for donors matched at the HLA-C locus.\n* Body weight of at least 40 kilograms and at least 12 years of age\n* Willing and able to undergo mobilized peripheral blood apheresis\n* In general good health as determined by the medical provider\n* Adequate organ function defined as:\n\n  * Hematologic: hemoglobin, WBC, platelet within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)\n  * Hepatic: ALT \\< 2 x upper limit of normal\n  * Renal: serum creatinine \\< 1.8 mg/dl\n* Performance of a donor infectious disease screen panel including CMV Antibody, Hepatitis B Surface Antigen, Hepatitis B Core Antibody, Hepatitis C Antibody, HIV 1/2 Antibody, HTLVA 1/2 Antibody, Treponema, and Trypanosoma Cruzi (T. Cruzi) plus HBV, HCV, WNV, HIV by nucleic acid testing (NAT); and screening for evidence of and risks factors for infection with Zika virus, or per current standard institutional donor screen - must be negative for HIV and active hepatitis B\n* Not pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of mobilization start\n* Voluntary written consent (parent/guardian and minor assent, if \\< 18 years) prior to the performance of any research related procedure",
            "healthyVolunteers": false,
            "sex": "ALL",
            "maximumAge": "65 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Margaret MacMillan, MD, Msc, FRCPC",
                    "role": "CONTACT",
                    "phone": "612-626-2961",
                    "email": "macmi002@umn.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Margaret MacMillan, MD, Msc, FRCPC",
                    "affiliation": "Masonic Cancer Center, University of Minnesota",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Masonic Cancer Center at University of Minnesota",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lisa Burke, RN",
                            "role": "CONTACT",
                            "phone": "612-273-8482",
                            "email": "lburke3@Fairview.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000740",
                    "term": "Anemia"
                },
                {
                    "id": "D000009190",
                    "term": "Myelodysplastic Syndromes"
                },
                {
                    "id": "D000000741",
                    "term": "Anemia, Aplastic"
                },
                {
                    "id": "D000005199",
                    "term": "Fanconi Anemia"
                },
                {
                    "id": "D000080983",
                    "term": "Bone Marrow Failure Disorders"
                },
                {
                    "id": "D000010198",
                    "term": "Pancytopenia"
                },
                {
                    "id": "D000019871",
                    "term": "Dyskeratosis Congenita"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000029502",
                    "term": "Anemia, Hypoplastic, Congenital"
                },
                {
                    "id": "D000080984",
                    "term": "Congenital Bone Marrow Failure Syndromes"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000049914",
                    "term": "DNA Repair-Deficiency Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000095542",
                    "term": "Cytopenia"
                },
                {
                    "id": "D000012868",
                    "term": "Skin Abnormalities"
                },
                {
                    "id": "D000000013",
                    "term": "Congenital Abnormalities"
                },
                {
                    "id": "D000040181",
                    "term": "Genetic Diseases, X-Linked"
                },
                {
                    "id": "D000012873",
                    "term": "Skin Diseases, Genetic"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M4070",
                    "name": "Anemia",
                    "asFound": "Anemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4071",
                    "name": "Anemia, Aplastic",
                    "asFound": "Aplastic Anemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8341",
                    "name": "Fanconi Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M8342",
                    "name": "Fanconi Anemia",
                    "asFound": "Fanconi Anemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14164",
                    "name": "Preleukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M12145",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13118",
                    "name": "Pancytopenia",
                    "asFound": "Bone Marrow Failure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21754",
                    "name": "Dyskeratosis Congenita",
                    "asFound": "Dyskeratosis Congenita",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2241",
                    "name": "Bone Marrow Failure Disorders",
                    "asFound": "Bone Marrow Failure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23455",
                    "name": "Anemia, Hypoplastic, Congenital",
                    "relevance": "LOW"
                },
                {
                    "id": "M2242",
                    "name": "Congenital Bone Marrow Failure Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M26131",
                    "name": "DNA Repair-Deficiency Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3170",
                    "name": "Cytopenia",
                    "relevance": "LOW"
                },
                {
                    "id": "M12",
                    "name": "Congenital Abnormalities",
                    "relevance": "LOW"
                },
                {
                    "id": "M15672",
                    "name": "Skin Abnormalities",
                    "relevance": "LOW"
                },
                {
                    "id": "M24877",
                    "name": "Genetic Diseases, X-Linked",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15676",
                    "name": "Skin Diseases, Genetic",
                    "relevance": "LOW"
                },
                {
                    "id": "T460",
                    "name": "Aplastic Anemia",
                    "asFound": "Aplastic Anemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2270",
                    "name": "Fanconi Anemia",
                    "asFound": "Fanconi Anemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1464",
                    "name": "Congenital Aplastic Anemia",
                    "relevance": "LOW"
                },
                {
                    "id": "T2272",
                    "name": "Fanconi Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "T3993",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1976",
                    "name": "Dyskeratosis Congenita",
                    "asFound": "Dyskeratosis Congenita",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008775",
                    "term": "Methylprednisolone"
                },
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000008558",
                    "term": "Melphalan"
                },
                {
                    "id": "D000002066",
                    "term": "Busulfan"
                },
                {
                    "id": "D000069283",
                    "term": "Rituximab"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                },
                {
                    "id": "D000074323",
                    "term": "Alemtuzumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000018696",
                    "term": "Neuroprotective Agents"
                },
                {
                    "id": "D000020011",
                    "term": "Protective Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11541",
                    "name": "Melphalan",
                    "asFound": "Controlled Study",
                    "relevance": "HIGH"
                },
                {
                    "id": "M373",
                    "name": "Rituximab",
                    "asFound": "Infusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11749",
                    "name": "Methylprednisolone",
                    "asFound": "Fixed",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1833",
                    "name": "Methylprednisolone Acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M11750",
                    "name": "Methylprednisolone Hemisuccinate",
                    "relevance": "LOW"
                },
                {
                    "id": "M14120",
                    "name": "Prednisolone",
                    "relevance": "LOW"
                },
                {
                    "id": "M229449",
                    "name": "Prednisolone acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M211887",
                    "name": "Prednisolone hemisuccinate",
                    "relevance": "LOW"
                },
                {
                    "id": "M248881",
                    "name": "Prednisolone phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M5336",
                    "name": "Busulfan",
                    "asFound": "Anesthetic",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M1347",
                    "name": "Alemtuzumab",
                    "asFound": "Transcranial Direct Current Stimulation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20773",
                    "name": "Neuroprotective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M21869",
                    "name": "Protective Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "NeuroAg",
                    "name": "Neuroprotective Agents"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                }
            ]
        }
    },
    "hasResults": false
}